肝癌是我国最常见的恶性肿瘤之一。近年来，我国肝癌诊疗领域取得巨大进步，部分大的医疗中心的诊疗水平已位居世界前列。但我国肝癌治疗的整体疗效并不理想，5年生存率仅为14.1%，显著低于东亚地区平均水平，其症结在于预防、诊断和治疗的不规范。主要体现在不同科室间缺乏协作，不同地域医疗资源分配不均，医疗质量评价体系存在缺陷，诊疗规范推广力度不足。需要通过推广肝癌多学科诊疗模式，改善医疗资源分布不平衡现状，完善医疗质量评价体系和加大诊疗规范推广力度等方面，促进我国肝癌外科临床诊治规范化。

Hepatocellular carcinoma（HCC）is one of the most common malignant tumors in China. In recent years，great progress has been made in the field of liver cancer diagnosis and treatment in China，and some medical centers have ranked among the top HCC centers in the world. However，therapeutic effect of HCC in China is unsatisfactory. The 5-year survival rate of Mainland Chinese patients is only 14.1%，which is significantly lower than the average level in East Asia（Close to 30%）. The crux of this lies in the irregularities of prevention，diagnosis and treatment. It is mainly reflected in the lack of cooperation between different departments，uneven distribution of medical resources in different regions，defects in medical quality evaluation system，and insufficient promotion of diagnosis and treatment guideline. It is necessary to promote the standardization of clinical diagnosis and treatment of HCC in China by promoting the multi-disciplinary diagnosis and treatment mode in HCC treatment，balancing the distribution of medical resources，improving the medical quality evaluation system and strengthening the promotion of diagnosis and treatment guidelines.